SIETES :: 93213 citas

Resultados de la búsqueda por DERMATITIS EXFOLIATIVA

1.

Anónimo. Ustekinumab (Stelara): risk of exfoliative dermatitis. Drug Safety Update 2015;8:2. [Ref.ID 98836]

2.

Anónimo. Ziprasidone (marketed as Geodon and generics): Drug Safety Communication - Rare but potentially fatal skin reactions. U.S. Food and Drug Administration 2014:11 de diciembre. [Ref.ID 98379]

3.

Gold R, Glovannoni G, Selmaj KH, Havrdova E, Montalban X, Radue E-W, Stefoski D, Robinson R, Riester K, Rana J, Elkins J, O'Neill G, for the SELECT study investigators. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet 2013;381:2167-75. [Ref.ID 95716]

4.

Saldha S, Calabresi PA. Anti-interleukin-2 receptor alpha for multiple sclerosis?. Lancet 2013;381:2141-3. [Ref.ID 95708]

5.

Anónimo. Sitagliptine: allergies graves. Prescrire 2008;28:907. [Ref.ID 84643]

6.

Anónimo. Ibritumomab tiuxetan therapeutic regimen: cutaneous reactions. WHO Drug Information 2005;19:293. [Ref.ID 76290]

7.

Anónimo. Systemic reactions to Imiquimod. Med Lett Drugs Ther 2004;46:92. [Ref.ID 71855]

8.

Anónimo. US warning for valdecoxib. Scrip 2002;2800:21. [Ref.ID 64132]

9.

Domínguez Ortega J, Trindade C, Alonso Llamazares A, Castellano Bravo A, Álvarez-Lovel M C, Martínez-Cócera C. Hipersensibilidad al alopurinol. Eficacia de un protocolo de desensibilización en tres casos. An Med Interna 2001;18:27-8. [Ref.ID 54687]

10.

Knowles SR, Uetrecht J, Shear NH. Idiosyncratic drug reactions: the reactive metabolite syndromes. Lancet 2000;356:1587-91. [Ref.ID 53552]

11.

Castellsagué J, García Rodríguez A, Duque A, Pérez Gutthann S. Risk of severe skin disorders in users of oral antifungals. Pharmacoepidemiol Drug Saf 2000;9:S35. [Ref.ID 53196]

12.

Cuxart M, Just M, Sans R, Matas M. Dermatitis exfoliativa generalizada por eritropoyetina. Med Clin (Barc) 2000;115:158. [Ref.ID 51979]

13.

Queffeulou G, Lebrun-Vignes B, Wheatley P, Montagnac R, Mignon F. Allergy to icodextrin. Lancet 2000;356:75. [Ref.ID 51685]

14.

Brasil MTLRF, Opromolla VA, Marzliak M L C, Nogueira W. Results of a surveillance system for adverse effects in leprosy's WHO/MDT. Int J Lepr Other Mycobact Dis 1996;64:97-103. [Ref.ID 33853]

15.

Council for International Organizations of Medical Sciences (CIOMS). Harmonizing the use of adverse-drug reaction terms. Definitions of terms and minimum requirements for their use: repiratory disorders and skin disorders. Pharmacoepidemiol Drug Saf 1997;6:115-27. [Ref.ID 32149]

16.

Arrowsmith JB, Creamer JI, Bosco L. Severe dermatologic reactions reported after treatment with tocainide. Ann Intern Med 1987;107:693-6. [Ref.ID 12195]

17.

Brogden RN. Pyrazolone derivatives. Drugs 1986;32:60-70. [Ref.ID 10735]